Eldercare & Longevity Tech
Aging biology has become one of the next major healthcare frontiers — and women live longer, disproportionately bearing its costs.
raised by Function Health & Neko Health combined
Across just four total funding rounds.
Loyal’s 2026 Series C
One of the sector’s largest single rounds this year.
longevity startups raised capital in the last 12 months
Visible but not yet broad — a specialist-conviction market, not a standardized allocation.
Inside the category
Longevity diagnostics & biomarkers
Testing platforms aiming to catch age-related decline earlier.
- Function Health ($298M Series B, $2.5B valuation)
- Neko Health
Longevity biotech & therapeutics
Drug and therapeutic development targeting aging biology directly.
- Loyal ($100M Series C)
- NewLimit ($435M Series C)
- Altos Labs ($3B raise)
- BioAge Labs ($170M Series C)
- Retro Biosciences ($90M)
- Junevity ($20M seed)
- Cleara Biotech ($45M)
- Selphagy ($18M Series A)
Why this fits women investors specifically
Women live longer than men on average, meaning they disproportionately experience the later-life health conditions this sector is built to address — and disproportionately manage care decisions for aging parents and partners along the way. That lived proximity is exactly the kind of insight gender-lens investors say they look for.
How to get exposure
Dedicated longevity funds exist (Apollo Health Ventures, age1) and write checks from $500K into early-stage companies — a more direct thesis-driven entry point than most sectors here, though still a specialist rather than generalist allocation.
The case against
Longevity spans two very different risk profiles that get sold as one category. Biology-stage companies carry full clinical risk: long timelines, binary outcomes, and capital requirements that dilute an early cheque heavily. Care and monitoring companies carry commercial risk instead, which is more legible but competes with entrenched health incumbents. Buying “longevity” without deciding which of the two you are underwriting is the most common error in this category. The field also attracts consumer claims that run ahead of the evidence, and regulatory attention tends to follow that eventually.
How this category returns capital
On the biology side, liquidity comes almost entirely from pharmaceutical acquisition or from an IPO window that opens and closes with the wider biotech cycle — neither of which an angel controls, and both of which can sit years past the point at which the science works. On the services side the acquirers are health systems and insurers, at operating multiples. Dedicated funds writing from $500K exist, and going through one buys diversification across that split rather than a bet on a single mechanism. For a direct cheque, the honest planning assumption is a decade.
What to weigh before writing a cheque
- The category doesn’t yet behave like a standardized portfolio allocation — investors are backing specific scientific theses, not buying broad sector exposure.
- Biotech-heavy longevity plays carry longer development timelines and higher binary risk than software-driven care-economy plays.
Sources
Figures reflect the most recent public reporting as of 2026. Named companies are illustrative of funding activity, not investment recommendations.